BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 25451866)

  • 1. Monitoring IgA multiple myeloma: immunoglobulin heavy/light chain assays.
    Katzmann JA; Willrich MA; Kohlhagen MC; Kyle RA; Murray DL; Snyder MR; Rajkumar SV; Dispenzieri A
    Clin Chem; 2015 Feb; 61(2):360-7. PubMed ID: 25451866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heavy/light chain assay in the monitoring of multiple myeloma.
    Ting HY; Sthaneshwar P; Bee PC; Shanmugam H; Lim M
    Pathology; 2019 Aug; 51(5):507-511. PubMed ID: 31253381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heavy/light chain specific immunoglobulin ratios provides no additional information than serum proteins electrophoresis and immunofixation for the diagnosis and the follow-up of intact immunoglobulin multiple myeloma patients.
    Beaumont-Epinette MP; Moreau C; Besnard S; Latute F; Collet N; Sebillot M; Grosbois B; Bendavid C; Guenet L; Decaux O
    Pathol Biol (Paris); 2015 Sep; 63(4-5):215-21. PubMed ID: 26319969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of the relationship of heavy/light chain pairs of immunoglobulin (Hevylite) to the results of gel electrophoresis and nefelometric examination of serum proteins at the time of multiple myeloma diagnosis].
    Ščudla V; Lochman P; Pika T; Zapletalová J; Minařík J; Bačovský J
    Cas Lek Cesk; 2015; 154(6):292-302. PubMed ID: 26750626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma.
    Boyle EM; Fouquet G; Guidez S; Bonnet S; Demarquette H; Dulery R; Herbaux C; Noel MP; Manier S; Schraen S; Onraed B; Faucompré JL; Hennache B; Petillon MO; Mathiot C; Avet-Loiseau H; Facon T; Harding SJ; Moreau P; Leleu X
    Cancer; 2014 Dec; 120(24):3952-7. PubMed ID: 25116271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.
    Ludwig H; Milosavljevic D; Zojer N; Faint JM; Bradwell AR; Hübl W; Harding SJ
    Leukemia; 2013 Jan; 27(1):213-9. PubMed ID: 22955329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgMκ and IgMλ Measurements for the Assessment of Patients with Waldenström's Macroglobulinaemia.
    Boyle E; Manier S; Lejeune J; Fouquet G; Guidez S; Bonnet S; Debarri H; Demarquette H; Dulery R; Gay J; Hennache B; Onraed B; Faucompré JL; Schraen S; Facon T; Avet-Loiseau H; Chevret S; Leblond V; Harding S; Leleu X
    Clin Cancer Res; 2016 Oct; 22(20):5152-5158. PubMed ID: 27169996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heavy/light chain assay as a biomarker for diagnosis and follow-up of multiple myeloma.
    Chae H; Han E; Yoo J; Lee J; Lee JJ; Cha K; Kim M; Kim Y; Lee SE; Min CK
    Clin Chim Acta; 2018 Apr; 479():7-13. PubMed ID: 29324245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the diagnostic performances of IgA heavy and light chain pairs in patients with IgA monoclonal gammopathy.
    Wolff F; Debaugnies F; Rozen L; Willems D; Brohet F; Brauner J; Stordeur P
    Clin Biochem; 2013 Jan; 46(1-2):79-84. PubMed ID: 23041246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analytical performance and diagnostic potential of immunoassays determining intact immunoglobulin kappa/lambda ratios in monoclonal gammopathies.
    Eckold J; Poenisch W; Drogies T; Kratzsch J; Teupser D; Thiery J; Bruegel M
    Clin Lab; 2014; 60(9):1491-500. PubMed ID: 25291945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal Heavy/Light Chain Ratio and Matched Pair Suppression Increase Residual Disease Detection Sensitivity in Patients With Multiple Myeloma With Deep Responses.
    Miyazaki K; Suzuki K
    Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):293-296. PubMed ID: 29472112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoglobulin heavy chain/light chain pairs (HLC, Hevylite™) assays for diagnosing and monitoring monoclonal gammopathies.
    Kraj M
    Adv Clin Exp Med; 2014; 23(1):127-33. PubMed ID: 24596015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Within-subject biological variation of pairs of heavy/light immunoglobulin IgM chains (HLC IgM κ and λ) is low and requires monitoring: A comparison with HLC IgA, HLC IgG, and free light immunoglobulin chains (FLC) in healthy subjects.
    Jabor A; Kubíček Z; Komrsková J; Sečník P; Vacková T; Vymětalík J; Franeková J
    Clin Chim Acta; 2018 Nov; 486():311-312. PubMed ID: 30125534
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients.
    Batinić J; Perić Z; Šegulja D; Last J; Prijić S; Dubravčić K; Volarić L; Sertić D; Radman I; Bašić-Kinda S; Matišić D; Batinić D; Labar B; Nemet D
    Croat Med J; 2015 Jun; 56(3):263-71. PubMed ID: 26088851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analytical validation of the Hevylite assays for M-protein quantification.
    Jacobs JFM; Haagen IA; Lodder A; van der Kroft C; de Kat Angelino CM; Croockewit S; Nieuwenhuys E; Gelderman KA
    Clin Chem Lab Med; 2018 Jun; 56(7):1169-1175. PubMed ID: 29397379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies.
    Greil C; Ihorst G; Gaiser F; Salzer U; Bisse E; Kastritis E; Ludwig H; Wäsch R; Engelhardt M
    Eur J Haematol; 2017 Nov; 99(5):449-458. PubMed ID: 28886228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma.
    Ludwig H; Milosavljevic D; Berlanga O; Zojer N; Hübl W; Fritz V; Harding S
    Am J Hematol; 2016 Mar; 91(3):295-301. PubMed ID: 26662888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of serum M-protein concentration from polyclonal immunoglobulins: an alternative to serum protein electrophoresis and standard immunochemical procedures.
    Bergón E; Miravalles E
    Clin Chem Lab Med; 2008; 46(8):1156-62. PubMed ID: 18605957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.
    Scudla V; Lochman P; Pika T; Minarik J; Zapletalova J; Bacovsky J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Mar; 160(1):84-93. PubMed ID: 26365929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.